 BRISBANE, Calif.--BUSINESS WIRE--Sangamo Therapeutics, Inc. Nasdaq: SGMO, a genomic medicine company, announced today that Chief Financial Officer Sung Lee is leaving the Company to pursue a new opportunity overseas. Mr. Lees last day of employment will be February 1, 2021. Sung has contributed significantly to Sangamos evolution, helping us build a strong cash position to advance proprietary medicines for patients in need as we begin a year with several potential catalysts, said Sandy 